Edwards Lifesciences Corp.says its recent launches of the Sapien 3 in Europe and Sapien XT in the U.S. are helping to expand the transcatheter aortic valve replacement patient population while helping Edwards keep its leadership in the TAVR market.
The company reported July 29 that its global transcatheter valve sales grew about 19 percent during the second quarter of 2014 to $219.7 million, including $92 million in U.S. sales....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?